Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

THE TRUTH ABOUT: 61 | History Defined

Commentary: There is much we still don’t know about giving 5- to 11-year-olds a COVID-19 vaccine

Should children ages 5 to 11 receive the COVID-19 vaccine? This is a difficult question without an easy answer, something you wouldn’t know from the strident opinions of politicians and health experts.

Chicago Tribune

FDA clears way for millions to get additional COVID-19 boosters

WASHINGTON — U.S. regulators cleared second booster doses of COVID-19 vaccine from Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE for adults 50 and older, making millions more people eligible for the shots as concern grows about a potential new wave of infections.

Tribune News Service

Infectious omicron BA.2 now dominant in US, with coronavirus spring rise likely

LOS ANGELES — The highly infectious BA.2 omicron subvariant is now the dominant version of the coronavirus circulating in the United States, according to federal estimates, a development that is triggering fresh concerns of a potential springtime wave.

Los Angeles Times

From analysis to the latest developments in health,
read the most diverse news in one place.

FDA Approves ViiV Healthcare's Cabenuva For Virologically Suppressed Adolescents With HIV

The FDA has approved ViiV Healthcare's Cabenuva (cabotegravir, rilpivirine) for HIV-1 in virologically suppressed adolescents. The approval covers patients aged 12 years or older and weighing at least 35kg on a stable antiretroviral regimen, with no history of treatment failure and no known or suspected resistance to either cabotegravir or rilpivirine. The regimen…

Benzinga

LV=’s on board with £511,000 bonus for boss despite shambles of failed sale

Mark Hartigan has been given £511,000 bonus for 2021 – a humbler CEO would have let the dust settle

The Guardian - UK

US regulators approve 2nd COVID booster for those aged 50 and up

US has seen a small uptick in new COVID-19 cases over the past week, raising concern that infections could surge again.

Al Jazeera

FDA Authorizes Fourth Dose Of Moderna, Pfizer/BioNTech COVID-19 Vaccines For Older People

The FDA has approved a second round of the Moderna Inc (NASDAQ:

Benzinga

Read news from The Economist, FT, and more,
with one subscription

US FDA approves second Covid booster for Americans 50 and older

Immunocompromised people also eligible for second booster, with CDC now to decide how and when such doses are offered

The Guardian - US

FDA clears way for millions to get additional COVID-19 boosters

U.S. regulators cleared second booster doses of COVID-19 vaccine from Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE for adults 50 and older, making millions more people eligible for the shots as concern grows about a potential new wave of infections.

Tribune News Service

FDA clears way for millions to get additional COVID-19 boosters

Tribune News Service

FDA approves another COVID booster for 50 and up

The Food and Drug Administration’s decision opens a fourth dose of the Pfizer or Moderna vaccines to those people at least four months after their previous booster.

Chicago Sun-Times

FDA approves another Pfizer, Moderna Covid booster for 50 and up

US regulators are allowing people 50 and older to get another booster dose of the Pfizer or Moderna Covid-19 vaccine

The Independent UK

CDC recommends second booster shot for Americans over 50

The plan is an effort to protect older Americans if there is another surge in infections.

Axios

Pfizer's Second Etrasimod Phase 3 Ulcerative Colitis Trial Hits Primary Goal

Pfizer Inc (NYSE:PFE) has announced topline results from a second Phase 3 study of etrasimod for moderately to severely active ulcerative colitis (UC). The 12- and 52-week ELEVATE UC 52 follow the recent announcement of 12-week findings from the ELEVATE UC 12 trial. In this 52-week study, also known as ELEVATE UC 52,…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - US

Biden and allies vow to keep up Russia punishment for ‘brutal attacks in Ukraine’ – as it happened

US and European leaders pledge assistance for people inside Ukraine and for those fleeing country

The Times of India

World moves from shortages to possible glut of Covid-19 vaccines

NEW YORK: After racing to build capacity and meet once seemingly insatiable orders for Covid-19 shots, the global vaccine industry is facing waning demand as many late-to-market producers fight over a slowing market.

Benzinga

Pfizer's COVID-19 Oral Therapy To Be Tested In Hospitalized COVID-19 Patients In UK: Reuters

Pfizer Inc's (NYSE: PFE) oral COVID-19 therapy will be evaluated as a potential treatment for hospitalized COVID-19 patients in a major British trial.

Benzinga

Check Out What Whales Are Doing With PFE

A whale with a lot of money to spend has taken a noticeably bearish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 17 strange trades.

Get all your
news in one place.

100's of premium titles.
One news app.

AAP

Teen COVID boosters being considered

Case numbers of COVID-19 have been increasing across the country in recent days due to infections linked to an Omicron sub-variant.

Benzinga

Fosun Pharma Hopes Covid Vaccine Can Cure Its Ailing Margins

Key takeaways:

The Independent UK

Antiviral drug to be trialled in hospitalised Covid patients

Having already been approved for early-stage treatment of Covid, scientists will now assess how Paxlovid performs when administered to people hospitalised with infection

The Guardian - UK

Why the UK can’t rely on boosters to get through each new wave of Covid

The evidence suggests performance could be less predictable and effective in the future – though there are promising developments, says Danny Altmann, a professor of immunology at Imperial College London

Asharq Al-Awsat

2nd COVID Vaccine Booster Significantly Lowers Death Rate, Israeli Study Shows

Senior citizens who received a second booster of the Pfizer–BioNTech COVID-19 vaccination had a 78% lower mortality rate from the disease than those who got one only, a study from Israel showed on Sunday. The country's largest healthcare provider, Clalit Health Services, said the 40-day study included more than half…

Tribune News Service

COVID-19 boosters, BA.2 subvariant, treatments: 6 things we still need to keep an eye on

Coronavirus case numbers have plummeted across much of the U.S., including Texas, a promising sign that COVID-19 could finally be waning. But the pandemic is far from over, especially for older adults, people with disabilities and other vulnerable populations.

The Hindu

KTR showcases Telangana to pharma majors

Meets top leadership of Pfizer, Johnson & Johnson and GSK as part of his official tour to the US

1 … 60 61 62 63

People

Ketanji Brown Jackson

1,031 stories

Richard Nixon

1,025 stories

Alexandria OcasioCortez

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Imperial College London

322 stories

Pfizer Inc

313 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.